Elizabeth S. Koh

Elizabeth S. Koh

Auto-generated profile, based on publicly available information

Elizabeth S. Koh

Department of Otolaryngology – Head & Neck Surgery Weill Cornell Medicine New York New York USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CVCristina Valero
Cristina Valero
MGMahdi Golkaram
Mahdi Golkaram
JVJoris L. Vos
Joris L. Vos
BXBin Xu
Bin Xu
CFConall Fitzgerald
Conall Fitzgerald
LMLuc Morris
Luc Morris
BACKGROUND. Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is often an incurable disease, with patients experiencing median survival of under ten months and significant morbidity. While immune checkpoint blockade (ICB) drugs are effective in ~20% of patients, the remaining experience limited clinical benefit and are exposed to potential adverse effects and financial costs. Clinically approved biomarkers, such as tumor mutational burden (TMB), have modest predictive value in HNSCC. METHODS. We analyze clinical and genomic features, generated using whole-exome sequencing, in 133 ICB-treated R/M HNSCC patients, of whom 69 had virus-associated and 64 had non-virus-associated tumors. RESULTS. Hierarchical clustering of genomic data revealed six molecular subtypes characterized by a wide range of objective response rates and survival after ICB therapy. The prognostic importance of these 6 subtypes was validated in an external cohort. A random forest-based predictive model, using several clinical and genomic features, predicted progression-free survival (PFS), overall survival (OS), and response with greater accuracy than a model based on TMB alone. Recursive partitioning analysis identified three features (systemic inflammatory response index, TMB, and smoking signature) that classified patients into risk groups with accurate discrimination of PFS and OS. CONCLUSION. These findings shed light on the immunogenomic characteristics of HNSCC tumors that drive differential response to ICB and identify a clinical-genomic classifier that outperforms the current clinically approved biomarker of TMB. This validated predictive tool may help with clinical risk stratification in patients with R/M HNSCC for whom ICB is being considered.

25 January 2024 in Head & Neck
Verified
Journal Article
Closed access
EKElizabeth S. Koh
Elizabeth S. Koh
ADAnas Dabsha
Anas Dabsha
MRMohamed Rahouma
Mohamed Rahouma
KZKyle Zappi
Kyle Zappi
YSYashes Srinivasan
Yashes Srinivasan
DKDavid I. Kutler
David I. Kutler

9 January 2023 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
EKElizabeth S. Koh
Elizabeth S. Koh
FCFrank R. Chen
Frank R. Chen
SCSophia Chen
Sophia Chen
TQTheodore Quan
Theodore Quan
KLKaren L. Leung
Karen L. Leung
JYJason Yang
Jason Yang

20 March 2024 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
EKElizabeth S. Koh
Elizabeth S. Koh
APAbhinav Pandey
Abhinav Pandey
VBVictoria E. Banuchi
Victoria E. Banuchi
WKWilliam I. Kuhel
William I. Kuhel
ATAndrew Tassler
Andrew Tassler
DKDavid I. Kutler
David I. Kutler

17 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
MPManu Prasad
Manu Prasad
ACAlex T. Cheng
Alex T. Cheng
MMMarcel Mayer
Marcel Mayer
LJLouis Jansen
Louis Jansen
EKElizabeth Koh
Elizabeth Koh
LMLuc Morris
Luc Morris
Purpose: Recurrent and metastatic human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (R/M HPV+ HNSCC) remains largely incurable, with genetic drivers incompletely defined. We profiled the genetic landscape of R/M HPV+ HNSCC and functionally characterized genetic alterations strongly enriched in this cancer type. Experimental Design: We identified genetic alterations uniquely enriched in 159 R/M HPV+ tumors. High-priority alterations were functionally modeled, examining proliferation, clonogenicity, migration/invasion, apoptosis, therapy response, in vivo growth, metastasis, and immune contexture. Results: Compared with HPV+ primary tumors, R/M HPV+ tumors were enriched for TP53 mutations (prespecified FDR threshold met; OR, 6.23; P = 0.02) and were associated with poorer survival. Within R/M disease, cylindromatosis lysine 63 deubiquitinase (CYLD) alterations were specific to HPV+ tumors (21% vs. 0% in HPV−). TP53 mutations were predominantly clonal and associated with whole-genome duplication. Expression of TP53 gain-of-function (GOF) mutants (R175H, G245C, R273C) in HPV+ HNSCC cells increased clonogenic survival, migration/invasion, lung metastatic burden in vivo, and cisplatin IC50, without altering radiation sensitivity. CYLD knockdown accelerated cellular growth yet increased radiosensitivity. Transcriptomic analyses linked CYLD loss to NF-κB/TNFα pathway activation, a T cell–inflamed microenvironment, and checkpoint upregulation. Conclusions: R/M HPV+ HNSCC is genomically and functionally shaped by two axes with therapeutic implications: TP53 GOF mutations promote metastatic phenotypes and cisplatin resistance, whereas CYLD loss defines an HPV-specific subset with enhanced radiation sensitivity and immune activation. These data support using TP53 and CYLD as predictive biomarkers to guide investigation into precision strategies for systemic therapy choices, p53-targeted/Wee1 strategies, and radiotherapy–immunotherapy combinations in high-risk or R/M HPV+ HNSCC.